144 related articles for article (PubMed ID: 38669256)
21. Papillary mucinous metaplasia of the endometrium as a possible precursor of endometrial mucinous adenocarcinoma.
Yoo SH; Park BH; Choi J; Yoo J; Lee SW; Kim YM; Kim KR
Mod Pathol; 2012 Nov; 25(11):1496-507. PubMed ID: 22766790
[TBL] [Abstract][Full Text] [Related]
22. Frequent KRAS mutation in complex mucinous epithelial lesions of the endometrium.
Alomari A; Abi-Raad R; Buza N; Hui P
Mod Pathol; 2014 May; 27(5):675-80. PubMed ID: 24186144
[TBL] [Abstract][Full Text] [Related]
23. A Combined Morphologic and Molecular Approach to Retrospectively Identify KRAS-Mutated Mesonephric-like Adenocarcinomas of the Endometrium.
Kolin DL; Costigan DC; Dong F; Nucci MR; Howitt BE
Am J Surg Pathol; 2019 Mar; 43(3):389-398. PubMed ID: 30489318
[TBL] [Abstract][Full Text] [Related]
24. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
25. KRAS Mutant Status, p16 and β-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer.
Sideris M; Moorhead J; Diaz-Cano S; Bjarnason I; Haji A; Papagrigoriadis S
Anticancer Res; 2016 Oct; 36(10):5315-5324. PubMed ID: 27798894
[TBL] [Abstract][Full Text] [Related]
26. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.
Nakanishi R; Harada J; Tuul M; Zhao Y; Ando K; Saeki H; Oki E; Ohga T; Kitao H; Kakeji Y; Maehara Y
Int J Clin Oncol; 2013 Dec; 18(6):1042-8. PubMed ID: 23188063
[TBL] [Abstract][Full Text] [Related]
27. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
28. Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases.
Zannoni GF; Santoro A; Angelico G; Spadola S; Arciuolo D; Valente M; Inzani F; Pettinato A; Vatrano S; Fanfani F; Scambia G; Fraggetta F
Hum Pathol; 2019 Oct; 92():10-17. PubMed ID: 31269413
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic application of KRAS mutation testing in uterine microglandular proliferations.
Hong W; Abi-Raad R; Alomari AK; Hui P; Buza N
Hum Pathol; 2015 Jul; 46(7):1000-5. PubMed ID: 25997988
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas.
Woo T; Okudela K; Yazawa T; Wada N; Ogawa N; Ishiwa N; Tajiri M; Rino Y; Kitamura H; Masuda M
Lung Cancer; 2009 Sep; 65(3):355-62. PubMed ID: 19162366
[TBL] [Abstract][Full Text] [Related]
31. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
32. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
[TBL] [Abstract][Full Text] [Related]
33. Genomic Profiling of Stage II Colorectal Cancer Identifies Candidate Genes Associated with Recurrence-Free Survival, Tumor Location, and Differentiation Grade.
Dimberg J; Andersson RE; Haglund S
Oncology; 2020; 98(8):575-582. PubMed ID: 32408300
[TBL] [Abstract][Full Text] [Related]
34. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase IIβ binding protein 1 c.*229C>T (rs115160714) gene polymorphism and endometrial cancer risk.
Forma E; Wójcik-Krowiranda K; Jóźwiak P; Szymczyk A; Bieńkiewicz A; Bryś M; Krześlak A
Pathol Oncol Res; 2014 Jul; 20(3):597-602. PubMed ID: 24346708
[TBL] [Abstract][Full Text] [Related]
36. MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway.
Bao J; Yu Y; Chen J; He Y; Chen X; Ren Z; Xue C; Liu L; Hu Q; Li J; Cui G; Sun R
Cell Death Dis; 2018 Oct; 9(10):1045. PubMed ID: 30315225
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.
Projetti F; Durand K; Chaunavel A; Léobon S; Lacorre S; Caire F; Bessède JP; Moreau JJ; Coulibaly B; Labrousse F
Hum Pathol; 2013 Oct; 44(10):2116-25. PubMed ID: 23791006
[TBL] [Abstract][Full Text] [Related]
38. Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia.
Zauber P; Denehy TR; Taylor RR; Ongcapin EH; Marotta S; Sabbath-Solitare M
Int J Gynecol Cancer; 2015 Jun; 25(5):863-8. PubMed ID: 25768080
[TBL] [Abstract][Full Text] [Related]
39. KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma.
Fu T; Guzzetta AA; Jeschke J; Vatapalli R; Dave P; Hooker CM; Morgan R; Iacobuzio-Donahue CA; Liu B; Ahuja N
Int J Cancer; 2013 Jun; 132(11):2502-9. PubMed ID: 23065691
[TBL] [Abstract][Full Text] [Related]
40. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
Nout RA; Bosse T; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; van Eijk R; Ter Haar NT; Smit VT
Gynecol Oncol; 2012 Sep; 126(3):466-73. PubMed ID: 22609107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
